Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S. Magenau J, et al. Among authors: parkin b. Bone Marrow Transplant. 2017 Jan;52(1):59-65. doi: 10.1038/bmt.2016.188. Epub 2016 Jul 18. Bone Marrow Transplant. 2017. PMID: 27427921 Free PMC article. Clinical Trial.
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC. Magenau JM, et al. Among authors: parkin b. Ann Hematol. 2015 Jun;94(6):1033-41. doi: 10.1007/s00277-015-2349-4. Epub 2015 Mar 19. Ann Hematol. 2015. PMID: 25784222
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.
Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW. Song Y, et al. Among authors: parkin b. Bone Marrow Transplant. 2016 Apr;51(4):511-520. doi: 10.1038/bmt.2015.170. Epub 2015 Jul 20. Bone Marrow Transplant. 2016. PMID: 26191952 Free PMC article. Clinical Trial.
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR. Pawarode A, et al. Biol Blood Marrow Transplant. 2016 Jan;22(1):54-60. doi: 10.1016/j.bbmt.2015.07.021. Epub 2015 Jul 26. Biol Blood Marrow Transplant. 2016. PMID: 26211984 Free article. Clinical Trial.
α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.
Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, Riwes MM, Kennel M, Antin JH, Cutler CS, Ho VT, Alyea EP 3rd, Parkin BL, Yanik GA, Choi SW, Lewis EC, Dinarello CA, Koreth J, Reddy P. Magenau JM, et al. Blood. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746. Epub 2018 Feb 2. Blood. 2018. PMID: 29437593 Free PMC article. Clinical Trial.
Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival.
Chappell G, Geer M, Gatza E, Braun T, Churay T, Brisson J, Bixby D, Marini B, Perissinotti A, Frame D, Parkin B, Reddy P, Magenau J, Choi SW. Chappell G, et al. Among authors: parkin b. Bone Marrow Transplant. 2019 Sep;54(9):1518-1520. doi: 10.1038/s41409-019-0493-5. Epub 2019 Feb 26. Bone Marrow Transplant. 2019. PMID: 30809038 No abstract available.
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. D'Souza A, et al. Among authors: parkin b. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497. doi: 10.1016/j.bbmt.2019.04.005. Epub 2019 Apr 6. Biol Blood Marrow Transplant. 2019. PMID: 30959163 Free article. Clinical Trial.
Type 1 interferon to prevent leukemia relapse after allogeneic transplantation.
Magenau JM, Peltier D, Riwes M, Pawarode A, Parkin B, Braun T, Anand S, Ghosh M, Maciejewski J, Yanik G, Choi SW, Talpaz M, Reddy P. Magenau JM, et al. Among authors: parkin b. Blood Adv. 2021 Dec 14;5(23):5047-5056. doi: 10.1182/bloodadvances.2021004908. Blood Adv. 2021. PMID: 34607341 Free PMC article. Clinical Trial.
110 results